Aprea Therapeutics (NASDAQ:APRE – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a note issued to investors on Thursday,RTT News reports. They currently have a $11.00 price objective on the stock.
Aprea Therapeutics Trading Down 4.4%
Shares of NASDAQ APRE opened at $1.68 on Thursday. Aprea Therapeutics has a 12 month low of $1.41 and a 12 month high of $5.01. The firm has a market capitalization of $9.26 million, a PE ratio of -0.71 and a beta of 1.22. The firm has a fifty day simple moving average of $1.72 and a two-hundred day simple moving average of $2.51.
Aprea Therapeutics (NASDAQ:APRE – Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.01). Aprea Therapeutics had a negative return on equity of 68.39% and a negative net margin of 1,095.02%. The company had revenue of $0.16 million during the quarter. On average, sell-side analysts predict that Aprea Therapeutics will post -2.55 earnings per share for the current year.
Hedge Funds Weigh In On Aprea Therapeutics
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
Featured Stories
- Five stocks we like better than Aprea Therapeutics
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- EA Just Caught a Monster Upgrade: Bullish Breakout Ahead?
- What is MarketRank™? How to Use it
- 3 Stocks Hitting All-Time Highs With More Room to Run
- 3 Tickers Leading a Meme Stock Revival
- QuantumScape Soars 30%: What Drove the Next-Gen EV Stock’s Rally
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.